HumanexaHumanexaHumanexa
WelcomeSignalsCompaniesAssetsScenario AnalysisRegulatoryStrategy
InsightsNewslettersReportsBriefings
Pricing
WorkspaceTeamWatchlistsCollectionsSettings

Free

Intelligence Active

Collegium Pharma Intelligence Report

Intelligence report

Intelligence Report · ~12 min read

Collegium Pharma Intelligence Report

Generated from 3 signals · 2 evidence sources

Type

Company Intelligence Report

Generated

Jun 26, 2026

Confidence

Moderate Confidence · 67%

Evidence

18 items

Sources

7

Executive Summary

Synthesized assessment from linked signals, findings, and evidence relationships.

Collegium Pharma maintains an active intelligence profile across Pain Management, Opioid. 3 signals are linked with 0 investigate-priority items requiring leadership attention. Competitive pressure is low with high portfolio impact. Evidence coverage stands at 67% across 2 tracked sources. Highest-priority development: FDA approves sacituzumab govitecan-hziy as monotherapy and in combination with pembrolizumab for first-line treatment of triple-negative breast cancer. Regulatory precedent. Why this matters: sets a safety guidance precedent in the same sub-indication (pain) as Collegium Pharma; the same agency is already in play for this signal, so precedent weight is higher.

Key Developments

Material intelligence events ranked by strategic relevance.

  1. regulatory

    FDA approves sacituzumab govitecan-hziy as monotherapy and in combination with pembrolizumab for first-line treatment of triple-negative breast cancer

    Regulatory precedent may inform portfolio positioning

    View detail
  2. regulatory

    Quantitative Systems Pharmacology (QSP)-Based Dose Selection for Minimum Anticipated Biological Effect Level (MABEL) in First-in-Human (FIH) Trials

    Regulatory precedent may inform portfolio positioning

    View detail
  3. regulatory

    FDA AP — XTAMPZA ER (SUPPL)

    Regulatory precedent may inform portfolio positioning

    View detail
  4. regulatory

    FDA AP — XTAMPZA ER (SUPPL)

    Regulatory precedent may inform portfolio positioning

    View detail
  5. regulatory

    FDA Approves First Generic of Priftin (rifapentine) Tablets

    Regulatory precedent may inform portfolio positioning

    View detail
  6. regulatory

    FDA AP — NUCYNTA (SUPPL)

    Regulatory precedent may inform portfolio positioning

    View detail
  7. regulatory

    FDA AP — NUCYNTA (SUPPL)

    Regulatory precedent may inform portfolio positioning

    View detail
  8. regulatory

    FDA AP — NUCYNTA (SUPPL)

    Regulatory precedent may inform portfolio positioning

    View detail
  9. regulatory

    FDA AP — NUCYNTA ER (SUPPL)

    Regulatory precedent may inform portfolio positioning

    View detail
  10. regulatory

    FDA AP — NUCYNTA ER (SUPPL)

    Regulatory precedent may inform portfolio positioning

    View detail
  11. regulatory

    FDA AP — NUCYNTA (SUPPL)

    Regulatory precedent may inform portfolio positioning

    View detail
  12. regulatory

    FDA AP — NUCYNTA ER (SUPPL)

    Regulatory precedent may inform portfolio positioning

    View detail

Strategic Implications

Portfolio and competitive decisions informed by this intelligence profile.

Opportunity score 58 with buyer quality 7 (Emerging). Competitive pressure: Low. Portfolio impact: High.

Supporting Evidence

Evidence-backed items with source attribution and confidence disclosure.

  • FDA approves sacituzumab govitecan-hziy as monotherapy and in combination with pembrolizumab for first-line treatment of triple-negative breast cancer

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • Quantitative Systems Pharmacology (QSP)-Based Dose Selection for Minimum Anticipated Biological Effect Level (MABEL) in First-in-Human (FIH) Trials

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — XTAMPZA ER (SUPPL)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — XTAMPZA ER (SUPPL)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA Approves First Generic of Priftin (rifapentine) Tablets

    Moderate Confidence · 84%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — NUCYNTA (SUPPL)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — NUCYNTA (SUPPL)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — NUCYNTA (SUPPL)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — NUCYNTA ER (SUPPL)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — NUCYNTA ER (SUPPL)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — NUCYNTA (SUPPL)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — NUCYNTA ER (SUPPL)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — NUCYNTA (SUPPL)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — NUCYNTA ER (SUPPL)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — NUCYNTA (SUPPL)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

Related Intelligence

Deep links to signals, insights, companies, and assets in the Humanexa graph.

Signals

  • FDA Approves Supplement for XTAMPZA ER by Collegium Pharma

    Pain Management · Opioid

  • FDA Acceptance of NUCYNTA ER Supplement Application by Collegium Pharma

    Pain Management · Opioid

  • FDA Accepts Supplement Application for NUCYNTA (Tapentadol Hydrochloride)

    Pain Management · Opioid

PrivacyTermsRefund PolicyDisclaimerContact

© 2026 Humanexa. Intelligence for research workflows — not medical, legal, regulatory filing, or investment advice.